No, Contrave is not a GLP-1. It is a combination of naltrexone and bupropion that acts on appetite and reward pathways, not on GLP-1 receptors. A compounded oral GLP-1 from telos rx is a different category of medicine entirely.
The confusion is fair. Both are prescription weight-management medicines described as working on appetite. Underneath that, they are unrelated drug classes.
What Contrave Actually Is
Contrave is an FDA-approved, brand-name extended-release tablet containing two older active ingredients in one pill: naltrexone hydrochloride, an opioid antagonist, and bupropion hydrochloride, an aminoketone antidepressant. The tablet strength on the label is 8 mg naltrexone HCl with 90 mg bupropion HCl.
Bupropion is the same active ingredient found in Wellbutrin and in the smoking-cessation product Zyban. Naltrexone is used in alcohol and opioid use disorder. Neither molecule is a peptide, and neither touches the incretin system.
The Contrave prescribing information on DailyMed indicates it alongside a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or overweight with at least one weight-related comorbid condition. More background sits in what Contrave is.
What a GLP-1 Actually Is
GLP-1 stands for glucagon-like peptide-1, a hormone the gut releases after eating. GLP-1 receptor agonists are engineered peptides that bind those receptors, slowing gastric emptying and acting on appetite signalling.
Wegovy is semaglutide, a GLP-1 receptor agonist. Zepbound is tirzepatide, a dual agonist at both the GIP and GLP-1 receptors, so a related but broader class. The pathway is covered in how GLP-1 medications work.
Contrave contains no peptide and does not bind GLP-1 receptors. Its combination is understood to act on appetite regulation and reward pathways instead. That is the answer; the rest is what the difference means in practice.
Contrave vs Wegovy vs Zepbound, Side by Side
| Contrave | Wegovy | Zepbound | telos rx compounded oral GLP-1 | |
|---|---|---|---|---|
| Active ingredients | Naltrexone HCl and bupropion HCl | Semaglutide | Tirzepatide | Compounded semaglutide or tirzepatide, ondansetron included |
| Is it a GLP-1? | No | Yes, GLP-1 receptor agonist | Dual GIP and GLP-1 agonist | Yes, same molecules, compounded |
| Where it acts | Appetite regulation and reward pathways | Incretin receptors, gastric emptying, appetite signalling | Incretin receptors, gastric emptying, appetite signalling | Same incretin pathway |
| Route | Oral tablet, swallowed whole | Weekly subcutaneous injection | Weekly subcutaneous injection | Daily sublingual dose, held under the tongue then swallowed |
| Regulatory status | FDA-approved | FDA-approved | FDA-approved | Not FDA-approved, prepared by licensed US compounding pharmacies under federal compounding regulations |
| Boxed warning | Yes, suicidal thoughts and behaviors | Yes, thyroid C-cell tumor class warning | Yes, thyroid C-cell tumor class warning | No FDA-approved label; provider reviews the same class risks |
| Reported side effects | Nausea, constipation, headache, blood pressure and heart rate increases | Nausea and diarrhea, usually transient in trials | Gastrointestinal, mostly mild to moderate in trials | Gastrointestinal effects of the same class |
| Prescription required | Yes | Yes | Yes | Yes, subject to medical approval by a licensed provider |
What the Trials Reported, and Why This Is Not a Head-to-Head
No direct head-to-head trial comparing Contrave with Wegovy or Zepbound is cited here. The figures below come from separate trials in different populations, with different durations and protocols, and cannot be read as a race between drugs.
The Contrave evidence base is the COR programme: four 56-week placebo-controlled trials (COR-I, COR-II, COR-BMOD, COR-Diabetes) enrolling 4,536 patients. In COR-I, the label reports a mean body-weight change of -5.4% against -1.3% for placebo, and 42% versus 17% reaching a 5% reduction.
In STEP 1, 1,961 adults took semaglutide or placebo for 68 weeks, with mean weight change of -14.9% against -2.4%. In SURMOUNT-1, 2,539 adults took tirzepatide or placebo for 72 weeks, with mean change from -15.0% to -20.9% across dose groups against -3.1%.
Different trials, different populations, different lengths. That describes the shape of the evidence for each class, not what any reader will experience. Closer analysis sits in does Contrave work?
If you came here for an oral option and it turns out you were really looking for a GLP-1, telos rx offers a compounded oral GLP-1 taken under the tongue. It is not Contrave, telos rx does not supply Contrave, and compounded medications are not FDA-approved.
See the oral GLP-1 optionThe Boxed Warning Difference
Contrave carries a boxed warning for suicidal thoughts and behaviors. Because it contains bupropion, the same active ingredient as several antidepressants, the label notes that antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents and young adults in short-term trials, and instructs that patients of all ages starting Contrave be monitored closely for worsening symptoms and for emerging suicidal thoughts and behaviors. Contrave is not approved for use in pediatric patients.
The label lists contraindications with no equivalent in the GLP-1 class: uncontrolled hypertension, seizure disorder or a history of seizures, bulimia or anorexia nervosa, abrupt discontinuation of alcohol, benzodiazepines, barbiturates or antiepileptic drugs, chronic opioid or opiate agonist use or acute opiate withdrawal, other bupropion-containing products, an MAOI within 14 days, and known allergy to any component. Detail is in Contrave side effects.
GLP-1 medicines carry their own class boxed warning relating to thyroid C-cell tumors, and their most commonly reported effects are gastrointestinal, covered in GLP-1 side effects research.
Route and Routine
Contrave is a swallowed tablet. The label describes a four-week escalation to a maintenance dosage of two tablets twice daily. That is label information, not guidance, and only a prescribing provider decides what is appropriate. Mechanics are in Contrave titration.
Wegovy and Zepbound are once-weekly injections. The compounded oral GLP-1 from telos rx is a daily dose held under the tongue for about 60 to 90 seconds, then swallowed. Sublingual absorption is lower than injection, and the provider sets the dose accordingly. Trade-offs are compared in oral versus injectable GLP-1.
Cost Works Differently in Each Category
Contrave is a branded FDA-approved medicine, so what a person pays turns on formulary placement and whether a plan covers weight-management drugs at all. Brand GLP-1s are equally insurance-dependent, usually at a higher list price. See Contrave cost and the semaglutide cost guide.
The compounded route is a cash-pay membership rather than a pharmacy benefit. As of publication, the telos rx page lists pricing from $9 a day on the prepaid three-month plan, with the online medical visit, expedited shipping and ondansetron included. Live pricing on the oral GLP-1 page takes precedence over anything quoted here.
Which Question Are You Actually Asking?
If the question is is Contrave a GLP-1, the answer is settled. If the question underneath is which category fits me, that is clinical, not a search-result decision. Some people are poor candidates for the GLP-1 class and reasonable candidates for Contrave, and some are the reverse.
Contrave has a real advantage the compounded route does not: it is FDA-approved, meaning the agency reviewed its safety and effectiveness data. Compounded oral semaglutide and tirzepatide are not FDA-approved. They are prepared by licensed US compounding pharmacies under federal compounding regulations, against a prescription for an individual patient.
Eligibility framing on the telos rx page generally starts at a BMI of 30 or higher, or 27 or higher with a weight-related condition. The service is online-first and asynchronous: you complete a written intake, a licensed provider reviews it in writing, and approval is not guaranteed.
Keep Reading
- What Is Contrave?
- Contrave vs Qsymia vs Phentermine
- Contrave Cost
- Contrave Side Effects
- Contrave Dosing
- Does Contrave Work?
- Contrave vs Wellbutrin
- Phentermine vs Semaglutide
Frequently Asked Questions
Is Contrave a GLP-1 drug?
No. Contrave is an extended-release combination of naltrexone and bupropion. It contains no peptide and does not act on GLP-1 receptors. GLP-1 medicines such as Wegovy are engineered peptides that bind incretin receptors. Both are prescription weight-management options, but they are entirely different drug classes with different labels and different risks.
Is Contrave the same as Ozempic or Wegovy?
No. Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist given as a weekly injection. Contrave is an oral tablet containing naltrexone and bupropion. They share a goal, chronic weight management, and share almost nothing else. Mechanism, route, trial evidence, side effects and contraindications all differ substantially.
Which works better, Contrave or Wegovy?
There is no head-to-head trial cited here, so that cannot be answered from the published figures. Contrave trials and semaglutide trials enrolled different populations for different durations under different protocols. Reported weight change was larger in the semaglutide trials, but cross-trial numbers are not a direct comparison, and candidacy depends on individual medical history.
Why does Contrave have a boxed warning?
Because it contains bupropion, the same active ingredient as several antidepressants. Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents and young adults in short-term trials. The label instructs that patients of all ages starting Contrave be monitored closely for worsening symptoms and emerging suicidal thoughts. Contrave is not approved for pediatric patients.
Does telos rx sell Contrave?
No. telos rx does not sell, prescribe or supply Contrave, and this article is educational rather than promotional. What telos rx offers is a compounded oral GLP-1, meaning sublingual semaglutide or tirzepatide, a different medicine in a different class. Compounded medications are not FDA-approved and require approval by a licensed provider.
Is there an oral GLP-1 alternative to Contrave?
An oral GLP-1 is not an alternative to Contrave in the clinical sense, because the two act on different pathways. If you want a GLP-1 without weekly injections, compounded sublingual semaglutide or tirzepatide is one route people explore. It is not FDA-approved, it is prescription-only, and suitability is decided by a licensed provider.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Only a licensed provider can say which path, if either, suits you. To explore the GLP-1 side without weekly injections, see the telos rx oral GLP-1 page, then complete the written intake at start an oral GLP-1 online visit. That is a compounded medicine that is not FDA-approved, it is not Contrave, and approval is subject to evaluation by a licensed provider.